Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study Of CNTY-101 At ASCO 2024 Annual Meeting In patients with Relapsed or Refractory, CD19-Positive B-Cell Malignancies
Portfolio Pulse from Benzinga Newsdesk
Century Therapeutics presented interim results from its Phase 1 ELiPSE-1 study of CNTY-101 at the ASCO 2024 Annual Meeting. The study showed a manageable safety profile and encouraging preliminary efficacy in patients with relapsed or refractory CD19-positive B-cell malignancies. Enrollment continues in the dose escalation phase.
June 03, 2024 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Century Therapeutics' interim results from the Phase 1 ELiPSE-1 study of CNTY-101 show a manageable safety profile and encouraging preliminary efficacy in relapsed or refractory CD19-positive B-cell malignancies. This could positively impact the stock price.
The interim results from the Phase 1 study indicate a manageable safety profile and encouraging efficacy, which are positive indicators for the future success of CNTY-101. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100